Stock market announcement archive

Lifecare – Successful completion of private placement

October 19, 2023
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN CANADA,JAPAN, AUSTRALIA OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH SUCHRELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOESNOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Reference is made to the announcement published on 19 October 2023 by LifecareAS […]
Read more

Lifecare – Contemplated private placement

October 19, 2023
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN CANADA,JAPAN, AUSTRALIA OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH SUCHRELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOESNOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Lifecare AS ("Lifecare" or the "Company") has retained Carnegie AS as bookrunnerand manager […]
Read more

Lifecare – Progress as planned towards ISO 13485 compliance

October 12, 2023
Bergen, Norway, October 12th, 2023: Today, Lifecare AS (LIFE), a clinical stagemedical sensor company developing the next generation Continuous Glucose Monitor(CGM), can disclose that Lifecare Laboratory (Mainz, Germany) is consideredready for ISO 13485 audit.ISO 13485 is a Quality Management System specific to medical devices and coversthe entire life cycle of a device, from design and […]
Read more

LIFE: Lifecare- Purchase software for automated production

October 2, 2023
Bergen, Norway, October 2nd, 2023: Lifecare AS (LIFE), a clinical stage medicalsensor company developing the next generation Continuous Glucose Monitor (CGM))has now placed the purchase order for automated production software. Reference is made to Lifecare's list of trigger events, as presented at thesemi-annual report of August 20th 2023 and later investor communication. Thelaunch of an […]
Read more

Lifecare – Sanofi Product Development Agreement Update

September 19, 2023
Reference is made to previous investor communication, i.e. September 23, 2021and later. Lifecare is engaged with Sanofi in a Product Development Agreementaimed at advancing the miniaturization of Lifecare's sensor technology forintegration into Lifecare's Sencell Continuous Glucose Monitoring system.Under the terms of the agreement, Sanofi has committed to provide fundingcontributions, supporting the further development of Lifecare's […]
Read more

LIFE: Towards market readiness

August 23, 2023
Lifecare has shown major progress in our plan to bring the smallest ContinuousGlucose Monitor (CGM) system to the market. Testing in live tissue,implementation of Quality Management System and set up of manufacturingcapabilities form the three main pillars in our market-oriented development. - The results from studies concluded in 1H 2023 and the status of the […]
Read more

LIFE: Lifecare 2023 semi-annual report and webcast

August 22, 2023
Lifecare AS will present 1H 2023 financial and operational status in a webcastWednesday 23 August. The webcast will be for all shareholders and interestedparties at 09:30 - 10:15 CET.The Swedish research powered investment bank Redeye AB will host the webcast.Lifecare's CEO Joacim Holter presents the company's Semi Annual report followedby a Q&A with Redeye's analyst […]
Read more

Lifecare sensor longevity experiment concluded: 6 months operational lifetime

July 18, 2023
Lifecare’s Sencell Continuous Glucose Monitoring (CGM) sensor has reached an operational lifetime of more than 24 weeks (172 days), with a sensor chemistry shelf life of almost 27 weeks (187 days). This achievement confirms the Sencell CGM technology potential and validates Lifecares expectation of a minimum 6-month sensor longevity. The longevity results were achieved by […]
Read more

LIFE: CLINICAL STUDY RESULTS PRESENTED AT AMERICAN DIABETES ASSOCIATION SCIENTIFIC SESSIONS 2023

June 27, 2023
Data from Lifecare's Clinical Development Study LFC-SEN-001 was presented at theAmerican Diabetes Association (ADA) Scientific Sessions 2023. Lifecare's posterpresentation reveals the study background, methods, and results. The resultsinclude an impressive mean average of absolute error (MARD) of 9,6%, positioningLifecares's Sencell technology with an accuracy that is acceptable fortherapeutic (medical) decisions such as insulin dose adjustments. […]
Read more

LIFE: LIFECARE STUDY CONFIRM CLINICAL ACCURACY IN LINE WITH GOLD STANDARD

June 20, 2023
Data from Lifecare's Clinical Development Study LFC-SEN-001 confirm that theCompany's Continuous Glucose Monitoring (CGM) system (Sencell) has a solidclinical accuracy: the mean average of absolute error (MARD) between Sencell andmatched relative reference values was 9,6%. In context, regulatory authorities expect a MARD below 10% to acknowledge CGMfor therapeutic (medical) decisions such as insulin dose adjustments. […]
Read more